<img alt="" height="1" width="1" />
Novartis says Signifor LAR drug helps control acromegaly disease
Reuters
ZURICH (Reuters) - Swiss drugmaker Novartis said on Monday a final-stage trial of its Signifor LAR therapy allowed for greater disease control in patients with the endocrine disorder acromegaly than existing therapies. Acromegaly is caused by a benign ...
Novartis drug Signifor® LAR shows superior efficacy in acromegaly patients not ...MarketWatch

all 2 news articles &raquo;


More...